On January 7, 2013, Onyx Pharmaceuticals, Inc. issued a press release announcing, among other things, preliminary 2012 net sales for Kyprolis™ (carfilzomib) for Injection. A copy of that press release is furnished as Exhibit 99.1 to this report.

This information in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in Exhibit 99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Onyx Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

(d) Exhibits

Exhibit Number                              Description

99.1             Press Release titled "Onyx Pharmaceuticals Announces 2013 Updates
                 and Reviews 2012 Achievements at J.P. Morgan Healthcare
                 Conference," dated January 7, 2013